Curofy
Enzalutamide Broadly Effective in Certain Prostate Cancers
The PREVAIL trial of enzalutamide (Xtandi, Medivation and Astellas Pharma) showed the efficacy of the agent in chemotherapy-naive metastatic castration-resistant prostate cancer (CRPC). New examination of the data by multinational investigators confirms its benefit across subgroups.
See this content immediately after install